"PBMs and health plans have spent years telling clients that, to some extent, it was kind of inappropriate ...

... to really aggressively manage these high-dollar specialty drug classes. The story line was these are unique products, they're life-saving therapies in many cases, they're treating very rare conditions and you don't want to get in the way of therapy here....But the landscape is totally different now. We've got healthy competition in a number of these high-dollar drug classes, and clients have an appetite to manage these classes."
— Josh Golden, practice leader, employer consulting, with Pharmaceutical Strategies Group LLC, told the audience at a recent AIS webinar on "Managing High-Cost Drug Categories."